MA28336A1 - Nouveau derive de benzimidazole a substitution 2-heteroaryle - Google Patents

Nouveau derive de benzimidazole a substitution 2-heteroaryle

Info

Publication number
MA28336A1
MA28336A1 MA29214A MA29214A MA28336A1 MA 28336 A1 MA28336 A1 MA 28336A1 MA 29214 A MA29214 A MA 29214A MA 29214 A MA29214 A MA 29214A MA 28336 A1 MA28336 A1 MA 28336A1
Authority
MA
Morocco
Prior art keywords
prevention
benzimidazole derivative
formula
atom
nitrogen
Prior art date
Application number
MA29214A
Other languages
English (en)
Inventor
Katsumasa Nonoshita
Yoshio Ogino
Makoto Ishikawa
Fumiko Sakai
Hiroshi Nakashima
Yoshikazu Nagae
Daisuke Tsukahara
Keisuke Arakawa
Teruyuki Nishimura
Jun-Ichi Eiki
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of MA28336A1 publication Critical patent/MA28336A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Il est proposé un activateur de la glucokinase et un remède et/ou moyen de prévention pour le diabète, et un remède et/ou moyen de prévention pour les complications chroniques du diabète telles que rétinopathie, néphropathie, névrose, cardiopathie ischémique, artérioslérose, et un remède et/ou un moyen de prévention pour l'obésité. Un activateur de la glucokinase caractérisé en ce qu'il contient un dérivé 2-hétéroaryle-benzimidazole substitué ayant la formule générale (I-0) ou son sel phartnaceutiquement acceptable : dans cette formule, X représente un atonie de carbone ou un atome d'azote ; X1, X2, X3 et X4 représentent chacun indépendamment un atome de carbone ou un atome d'azote ; l'anneau A représente un anneau hétéro-aromatique à 5 ou 6 éléments porteur d'azote de formule (II) : R1 représente un aryle, etc.; R2 représente un hydroxy etc.; R3 représente un -C1-6 alkyle, etc.; R4 représente un ¿C1-6 alkyle, etc.; X5 représente -O-, etc.; a représente un nombre entier égal à 1, 2 ou 3; q représente un nombre entier allant de 0 à 2; m indique un nombre entier allant de 0 à 2,
MA29214A 2003-12-29 2006-07-27 Nouveau derive de benzimidazole a substitution 2-heteroaryle MA28336A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003436992 2003-12-29
JP2004235696 2004-08-13

Publications (1)

Publication Number Publication Date
MA28336A1 true MA28336A1 (fr) 2006-12-01

Family

ID=34742165

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29214A MA28336A1 (fr) 2003-12-29 2006-07-27 Nouveau derive de benzimidazole a substitution 2-heteroaryle

Country Status (15)

Country Link
US (1) US7728025B2 (fr)
EP (1) EP1702919B1 (fr)
JP (1) JP4707560B2 (fr)
KR (1) KR20060105872A (fr)
AU (1) AU2004309287B2 (fr)
BR (1) BRPI0418212A (fr)
CA (1) CA2553160C (fr)
EC (1) ECSP066682A (fr)
IL (1) IL176451A0 (fr)
IS (1) IS8509A (fr)
MA (1) MA28336A1 (fr)
NO (1) NO20063475L (fr)
NZ (1) NZ548128A (fr)
RU (1) RU2329261C2 (fr)
WO (1) WO2005063738A1 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR20070085371A (ko) 2004-10-16 2007-08-27 아스트라제네카 아베 페녹시 벤즈아미드 화합물의 제조 방법
CA2586056C (fr) 2004-11-02 2012-03-13 Banyu Pharmaceutical Co., Ltd. Derives de benzimidazole aryloxy-substitues
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
CA2614746C (fr) 2005-07-09 2011-05-10 Astrazeneca Ab Derives d'heteroaryl benzamide utilises en tant qu'activateurs de la glk dans le traitement du diabete
EP1905769B1 (fr) * 2005-07-13 2017-03-29 Msd K.K. Dérivé du benzimidazole à substitution par un hétérocycle
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
EP1928874A1 (fr) * 2005-09-16 2008-06-11 AstraZeneca AB Composés hétérobicycliques utilisés comme activateurs de la glucokinase
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
US7625890B2 (en) 2005-11-10 2009-12-01 Smithkline Beecham Corp. Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
ATE545637T1 (de) * 2005-12-15 2012-03-15 Astrazeneca Ab Substituierte diphenylether, -amine, -sulfide und methane zur behandlung von atemwegserkrankungen
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
AU2007208351C1 (en) * 2006-01-23 2011-07-07 Amgen Inc. Aurora kinase modulators and method of use
PE20080359A1 (es) 2006-04-19 2008-06-06 Novartis Ag Compuestos de benzoxazol y benzotiazol 6-0-sustituidos y metodos de inhibicion de la senalizacion de csf-1r
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP2077267A4 (fr) * 2006-10-18 2010-04-07 Takeda Pharmaceutical Composé hétérocyclique fusionné
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
SA07280576B1 (ar) 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
UY30822A1 (es) 2006-12-21 2008-07-31 Astrazeneca Ab Fnueva forma cristalina de 3-{[5-azetidin-1-ylcabonyl)pyrazin-2-yl]oxy}-5-[1-methylethyloxy]-n-1h-pyrazol-3-ylbenzamida, composiciones conteniéndola, procesos de preparacion y aplicaciones
JPWO2008136428A1 (ja) * 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
JP5301456B2 (ja) 2007-11-12 2013-09-25 Ｍｓｄ株式会社 ヘテロアリールオキシキナゾリン誘導体
PT2239253E (pt) * 2008-02-06 2013-09-17 Daiichi Sankyo Co Ltd Novo derivado de fenilpirrole
EP2294066B9 (fr) 2008-04-28 2015-03-11 Janssen Pharmaceutica, N.V. Benzoimidazoles comme inhibiteurs de la prolyl hydroxylase
CA2732165A1 (fr) 2008-08-04 2010-02-11 Astrazeneca Ab Agents therapeutiques 414
JP2012500181A (ja) 2008-08-15 2012-01-05 Ｍｓｄ株式会社 アセチルピロリジニルインドール誘導体
US8609699B2 (en) * 2008-08-29 2013-12-17 Msd K.K. Oxotetrahydrofuran-2-yl-benzimidazole derivative
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
UY32799A (es) 2009-07-24 2011-02-28 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
BR112012010738A2 (pt) 2009-11-06 2019-09-24 Univ Vanderbilt ''aril e heteroaril sulfonas como potenciadores alostéricos de mglur4,composições e métodos de tratamento de disfunção neurológica''
PH12012501104A1 (en) * 2009-12-04 2014-10-14 Nissan Chemical Ind Ltd 2-pyridone compounds
KR20120118008A (ko) * 2009-12-18 2012-10-25 아이데닉스 파마슈티칼스, 인코포레이티드 5,5-융합 아릴렌 또는 헤테로아릴렌 간염 ｃ 바이러스 억제제
WO2011080176A1 (fr) 2009-12-31 2011-07-07 Novartis Ag Derives de pyrazine et leur utilisation dans le traitement de troubles neurologiques
PH12012500361A1 (en) 2010-07-13 2012-01-19 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
CN103429589A (zh) 2011-01-12 2013-12-04 诺瓦提斯公司 噁嗪衍生物及其在治疗神经障碍中的用途
US9273034B2 (en) 2011-10-25 2016-03-01 Janssen Pharmaceutica Nv Meglumine salt formulations of 1-(5,6-dichloro-1H-benzo[D]imidazol-2-yl)-1H-pyrazole-4-carboxylic acid
WO2015035223A1 (fr) 2013-09-09 2015-03-12 Peloton Therapeutics, Inc. Aryléthers et utilisations de ceux-ci
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016145045A1 (fr) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions s'utilisant dans le traitement du glioblastome
WO2016144826A1 (fr) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Pyridines substituées et leurs utilisations
US10807948B2 (en) 2015-03-11 2020-10-20 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
WO2016168510A1 (fr) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Thérapie combinée avec un inhibiteur de hif-2-alpha et un agent immunothérapeutique, et applications corresponantes
CN108349979B (zh) 2015-11-02 2021-04-09 詹森药业有限公司 [1,2,4]三唑并[1,5-a]嘧啶-7-基化合物
EA039102B1 (ru) 2016-11-02 2021-12-03 Янссен Фармацевтика Нв Соединения [1,2,4]триазоло[1,5-a]пиримидина в качестве ингибиторов pde2
CN109890824B (zh) 2016-11-02 2022-05-24 詹森药业有限公司 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶化合物
MY193511A (en) 2016-11-02 2022-10-17 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
KR20240035820A (ko) 2021-07-09 2024-03-18 플렉시움 인코포레이티드 Ikzf2를 조절하는 아릴 화합물 및 약학 조성물
WO2025111224A1 (fr) * 2023-11-21 2025-05-30 Fmc Corporation Composés bicycliques liés pour lutter contre les nuisibles invertébrés et combattre ceux-ci

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL134354C (fr) * 1963-05-23
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
EP0726260A1 (fr) 1995-02-08 1996-08-14 American Cyanamid Company (1,2,4)Thiadiazoles herbicides
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
KR20010015910A (ko) 1998-01-23 2001-02-26 로렌스 티. 마이젠헬더 옥사졸리디논 조합 라이브러리, 조성물 및 제조 방법
JP2000026430A (ja) * 1998-07-02 2000-01-25 Taisho Pharmaceut Co Ltd ２、５、６−置換ベンズイミダゾール化合物誘導体
PL351898A1 (en) * 1999-04-06 2003-06-30 Sankyo Co O-substituted derivatives of carboxylic acids
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
DE10238002A1 (de) 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
EP1598349B1 (fr) 2003-02-13 2011-07-27 Msd K.K. Nouveaux derives de 2-pyridinecarboxamide
NZ541824A (en) 2003-02-26 2010-04-30 Banyu Pharma Co Ltd Heteroarylcarbamoylbenzene derivatives as glucokinase activators
CA2586056C (fr) 2004-11-02 2012-03-13 Banyu Pharmaceutical Co., Ltd. Derives de benzimidazole aryloxy-substitues
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use

Also Published As

Publication number Publication date
BRPI0418212A (pt) 2007-04-27
EP1702919A4 (fr) 2008-11-12
ECSP066682A (es) 2006-10-25
CA2553160A1 (fr) 2005-07-14
JP4707560B2 (ja) 2011-06-22
KR20060105872A (ko) 2006-10-11
RU2329261C2 (ru) 2008-07-20
US7728025B2 (en) 2010-06-01
NZ548128A (en) 2010-05-28
NO20063475L (no) 2006-09-28
RU2006127420A (ru) 2008-02-10
CA2553160C (fr) 2010-09-28
JPWO2005063738A1 (ja) 2007-07-19
AU2004309287B2 (en) 2008-07-31
EP1702919A1 (fr) 2006-09-20
IL176451A0 (en) 2006-10-05
EP1702919B1 (fr) 2012-05-30
US20080070928A1 (en) 2008-03-20
WO2005063738A1 (fr) 2005-07-14
IS8509A (is) 2006-06-15
AU2004309287A1 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
MA28336A1 (fr) Nouveau derive de benzimidazole a substitution 2-heteroaryle
RU2375363C2 (ru) Пирролотриазиновые производные анилина, полезные в качестве ингибиторов киназы
RU2497807C2 (ru) Карбазольные соединения и терапевтические применения соединений
CA2582447A1 (fr) Aminopiperidines utilisees comme inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
CA2479133A1 (fr) Derives de 2,4-diaminopyrimidine
DE10178132T1 (de) Antivirales Mittel
EA200600990A1 (ru) Производные бензосульфониламинопиридин-2-ила и родственные соединения в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы 1 типа (11-бета-hsd-1) для лечения диабета и ожирения
BRPI0510365A (pt) composto, método de produção de um composto, antagonista do receptor nk2, pró-droga, agente farmacêutico, métodos para antagonizar um recpetor nk2 e para evitar ou tratar doenças gastrintestinais funcionais, e, uso do composto ou uma pró-droga do mesmo
MX2022006608A (es) Nuevos inhibidores de aurora cinasa y uso de los mismos.
CA2497868A1 (fr) Composes heterocycliques
CA2412941A1 (fr) Composes de piperidine s'utilisant en tant qu'inhibiteurs ccr-3
FI951417A0 (fi) Bifenyylijohdannaiset
MA30355B1 (fr) Derives d'azabicyclo [3. 1. 0] hexyle utilises comme modulateurs des recepteurs de la dopamine d3
WO2003024441A1 (fr) Nouvelle utilisation de composes tricycliques
TW200716528A (en) Cyclopropanecarboxamide derivatives
MY148434A (en) Fused bicyclic heteroaryl derivatives
RU2008119651A (ru) Производные дикарбоновых кислот и их применение
RU2010115337A (ru) Трициклические гетероциклические производные
CN111601797A (zh) 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用
JP2006523698A5 (fr)
RU2018133288A (ru) Комбинированные терапии для лечения спинальной мышечной атрофии
JP2018529643A (ja) ユビキチン化−プロテアソーム系に関連する化合物および薬学的組成物
RU2007116987A (ru) Новые соединения
MA50069B1 (fr) Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu'inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique
RU92016545A (ru) Гетероциклические соединения, способ их получения и фармацевтическая композиция